Join the Rybelsus group to help and get support from people like you.
Rybelsus News
FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads
WEDNESDAY, Sept. 17, 2025 — Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs, including popular weight loss medications. On Tu...
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 – Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with knee osteoarthritis...
Triple Dose Of Ozempic Safe, More Effective For Weight Loss
TUESDAY, Sept. 16, 2025 — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show. Obese f...
Half Discontinue Semaglutide for Weight Loss Within One Year
TUESDAY, Sept. 16, 2025 – Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual meeting of the European Association for the...
WHO Updates List of Essential Medicines to Include GLP-1s
TUESDAY, Sept. 9, 2025 – The World Health Organization published updated editions of its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to include new treatments...
FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S.
FRIDAY, Sept. 5, 2025 -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering ...
14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 – Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in...
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 – Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient...
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 – For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial,...
Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
MONDAY, Aug. 18, 2025 – For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14...
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 – In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by...
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
THURSDAY, Aug. 7, 2025 – A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have...
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Aug. 5, 2025 – For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION),...